Chalcones in cancer: Understanding their role in terms of QSAR

Current Medicinal Chemistry

Volumn 16, Issue 9, 2009, Pages 1062-1081

  Katsori, A M ^a   Hadjipavlou Litina, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anticancer activity; Chalcones; Cytoprotection; Lipophilicity; QSAR; Steric factors

Indexed keywords

1 (2,5 DIMETHOXYPHENYL) 3 [4 (DIMETHYLAMINO)PHENYL] 2 METHYL 2 PROPEN 1 ONE; 1,3 DIPHENYL 2 PROPENONE; 2 ARYLIDENEBENZOCYCLOALKONE DERIVATIVE; 2 CHLORO 2' 5' DIHYDROXYCHALCONE; 2' HYDROXY 4' METHOXYCHALCONE; AM 114; BORONIC ACID DERIVATIVE; BUTEIN; CHALCONE B; CHALCONE DERIVATIVE; COLCHICINE; COMBRETASTATIN A4; FLAVOKAWAIN A; ISOCORDOIN; ISOQUIRITIGENIN; LICOCHALCONE E; N [4 (3 ARYL 3 OXO 1 PROPENYL)PHENYLCARBONYL] 3,5 BIS(PHENYLMETHYLENE) 4 PIPERIDONE DERIVATIVE; PANDURATIN A; SD 400; STYRYLKETONE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; XANTHOHUMOL;

ANTINEOPLASTIC ACTIVITY; CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; NONHUMAN; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CHALCONES; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65649105091     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787581798     Document Type: Review

References (59)

1. Bohm, B. A. Introduction to flavonoids, Harwood Academic Publishers: Amsterdam, 1998.
2. Opletalovà, V.; Øièièáøová, P.; Šedivý, D.; Meltrová, D.; Køváková, J.; Chalcones NAD their heterocyclic analogues as potential medicaments. Folia Pharm. Univ. Carol. XXV, 2000, 21-23.
3. Liu, M.; Wilairat, P.; Go. M. L. Antimalarial alkoxylated and hydroxylated chalcones corrected: Structure-activity relationship analysis. J. Med. Chem., 2001, 44, 4443-52.
4. Stoyanov, E. V.; Champavier, Y.; Simon, A.; Basly, J. P. Efficient liquid-phase synthesis of 2′-hydroxychalcones. Bioorg. Med. Chem. Lett., 2002, 12, 2685.
5. Eddarir, S.; Cotelle, N.; Bakkour, Y.; Rolando, C.; An efficient synthesis of chalcones based on the Suzuki reaction. Tetrahedron Lett., 2003, 44, 5359-63.
6. Fan, X. S.; Zhang, Y. M. A simple access to chalcones via modified Mukaiyama aldol condensation promoted by SmI3/TMSCI. Chin. J. Chem., 2002, 20, 198-201.
7. Briot, A.; Baehr, C.; Brouillard, R.; Wagner, A.; Mioskowski, C. Concise synthesis of dihydrochalcones via palladium-catalyzed coupling of aryl halides and 1-aryl-2-propen-1-ols. J. Org. Chem., 2004, 69, 1374-7.
8. Dimmock, J. R.; Elias, D. W.; Beazely, M. A.; Kandepu, N. M. Bioactivities of chalcones. Curr. Med. Chem., 1999, 6, 1125-49.
9. Go, M. L.; Wu, X.; Liu, X. L. Chalcones: An update on cytotoxic and chemoprotective properties. Curr. Med. Chem., 2005, 12, 481-99.
10. Mojzis, J.; Varinska, L.; Mojzisova, G.; Kostova, I.; Mirossay, L. Antiangiogenic effects of flavonoids and chalcones. Pharmacol. Res., 2008, 57, 259-65.
11. Ducki, S. The development of chalcones as promising anticancer agents. IDrugs, 2007, 10, 42-6.
12. Carmeliet, P. Angiogenesis in health and disease. Nat. Med., 2003, 9, 653-60.
13. Koch, A. E. Angiogenesis as a target in rheumatoid arthritis. Ann. Rheum. Dis., 2003, 62, ii60-7.
14. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer., 2003, 3, 401-10.
15. López, S. N.; Castelli, M. V.; Zacchino, S. A.; Domínguez, J. N.; Lobo, G.; Charris-Charris, J.; Cortés, J. C.; Ribas, J. C.; Devia, C.; Rodríguez, A. M.; Enriz, R. D. Bioorg. In vitro antifungal evaluation and structure-activity relationships of a new series of chalcone derivatives and synthetic analogues, with inhibitory properties against polymers of the fungal cell wall. Med. Chem., 2001, 9, 1999-2013.
16. Rastelli, G.; Antolini, L.; Benvenuti, S.; Costantino, L.; Structural bases for the inhibition of aldose reductase by phenolic compounds. Bioorg. Med. Chem., 2000, 8, 1151-8.
17. Iwata, S.; Nishino, T.; Inoue, H.; Nagata, N.; Satomi, Y.; Nishino, H.; Shibata, S. Antitumorigenic activities of chalcones (II). Photoisomerization of chalcones and the correlation with their biological activities. Biol. Pharm. Bull., 1997, 20, 1266-70.
18. Ducki, S.; Forrest, R.; Hadfield, J. A.; Kendall, A.; Lawrence, N. J.; McGown, A. T.; Rennison, D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett., 1998, 8, 1051-6.
19. Yit, C. C.; Das, N. P. Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. Caner Lett., 1994, 82, 65-72.
20. Samoszuk, M.; Tan, J.; Chorn, G. The chalcone butein from Rhus verniciflua Stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts. BMC Complement Altern. Med., 2005, 5, 5.
21. Ramanathan, R.; Tan, C. H.; Das, N. P. Cytotoxic effect of plant polyphenols and fat-soluble vitamins on malignant human cultured cells. Caner Lett., 1992, 62, 217-24.
22. Iwashita, K.; Kobori, M.; Yamaki, K.; Tsushida, T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci. Biotechnol. Biochem., 2000, 64, 1813-20.
23. Pandey, M. K.; Sandur, S. K.; Sung, B.; Sethi, G.; Kunnumakkara, A. B.; Aggarwal, B. B. Butein, a Tetrahydroxychalcone, Inhibits Nuclear Factor (NF)-κB and NF-κB-regulated gene expression through direct inhibition of IκBα kinase β on cysteine 179 residue. J. Biol. Chem., 2007, 282, 17340-17350.
24. Peyrot, V.; Leynadier, D.; Sarrazin, M.; Briand, C.; Rodriquez, A.; Nieto, J. M.; Andreu, J. M. Interaction of tubulin and cellular microtubules with the new antitumor drug MDL 27048. A powerful and reversible microtubule inhibitor. J. Biol. Chem., 1989, 264, 21296-21301.
25. Edwards, M. L.; Stemerick, D. M.; Sunkara, P. S. Chalcones: A new class of antimitotic agents. J. Med. Chem., 1990, 33, 1948-54.
26. Lawrence, N. J.; McGown, A. T. The chemistry and biology of antimitotic chalcones and related enone systems. Curr. Pharm. Des., 2005, 11, 1679-93.
27. Yun, J. M.; Kweon, M. H.; Kwon, H.; Hwang, J. K.; Mukhtar, H. Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145. Carcinogenesis, 2006, 27, 1454-64.
28. Hsu, Y. L.; Kuo, P. L.; Tzeng, W. S.; Lin, C. C. Chalcone inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis. Food Chem. Toxicol., 2006, 44, 704-13.
29. Stoll, R.; Renner, C.; Hansen, S.; Palme, S.; Klein, C.; Belling, A.; Zeslawski, W.; Kamionka, M.; Rehm, T.; Mühlhahn, P.; Schumacher, R.; Hesse, F.; Kaluza, B.; Voelter, W.; Engh, R. A.; Holak, T. A. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry, 2001, 40, 336-44.
30. Achanta, G.; Modzelewska, A.; Feng, L.; Khan, S. R.; Huang, P. A Boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol. Pharmacol., 2006, 70, 426-33.
31. Zi, X.; Simoneau, A. R. Flavokawain, A. A novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res., 2005, 65, 3479-86.
32. Jung, J. I.; Lim, S. S.; Choi, H. J.; Cho, H. J.; Shin, H. K.; Kim, E. J.; Chung, W. Y.; Park, K. K.; Park, J. H. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J. Nutr. Biochem., 2006, 17, 689-96.
33. Nam, N. H.; Kim, Y.; You, Y. J.; Hong, D. H.; Kim, H. M.; Ahn, B. Z. Cytotoxic 2′,5′-dihydroxychalcones with unexpected antiangiogenic activity. Eur. J. Med. Chem., 2003, 38, 179-87.
34. Lee, Y. S.; Lim, S. S.; Shin, K. H.; Kim, Y. S.; Ohuchi, K. Jung, S. H. Anti-angiogenic and anti-tumor activities of 2′-hydroxy-4′-methoxychalcone. Biol. Pharm. Bull., 2006, 29, 1028-31.
35. Zhu, X. F.; Xie, B. F.; Zhou, J. M.; Feng, G. K.; Liu, Z. C.; Wei, X. Y.; Zhang, F. X.; Liu, M. F.; Zeng,Y. X.; Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2′,4′-dihydroxy-6′- methoxy-3′,5′-dimethylchalcone), a component from chinese herbal medicine. Mol. Pharmacol., 2005, 67, 1444-50.
36. Chang, H. J.; Yoon, G.; Park, J. S.; Kim, M. H.; Baek, M. K.; Kim, N. H.; Shin, B. A.; Ahn, B. W.; Cheon, S. H.; Jung, Y. D. Induction of apoptosis by the licochalcone E in endothelial cells via modulation of NF-kappaB and Bcl-2 Family. Biol. Pharm. Bull., 2007, 30, 2290-3.
37. a. Miranda, C. L.; Stevens, J. F.; Helmrich, A.; Henderson, M. C.; Rodriguez, R. J.; Yang, Y. H.; Deinzer, M. L.; Barnes, D. W.; Buhler, D. R. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem. Toxicol., 1999, 37, 271-85.
38. b. Delmulle, L.; Bellahcène, A.; Dhooge, W.; Comhaire, F.; Roelens, F.; Huvaere, K.; Heyerick, A.; Castronovo, V.; De Keukeleire, D. Anti-proliferative properties of prenylated flavonoids from hops (Humulus lupulus L.) in human prostate cancer cell lines. Phytomedicine, 2006, 13, 732-53.
39. Henderson, M. C.; Miranda, C. L.; Stevens, J. F.; Deinzer, M. L.; Buhler, D. R. Xenobiotica, 2000, 30, 235-51.
40. Albini, A,; Dell'Eva, R.; Venè, R.; Ferrari, N.; Buhler, DR.; Noonan, D. M.; Fassina, G. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J., 2006, 20, 527-9.
41. BioByte Corporation, C-QSAR database, 201 W Fourth str., Suite # 204, Claremont, CA 91711-4707, USA.
42. a. Hansch, C.; Leo, A. J. Exploring QSAR: Fundamentals and applications in chemistry and Biology, American Chemical Society, Washington, D.C. 1995.
43. b. Hansch, C.; Leo, A. J.; Hoekman, D. Exploring QSAR: Hydrophobic, Electronic and steric Constants, American Chemical Society,Washington, D.C. 1995.
44. Cramer, R. D.; Bruce, J. D.; Patterson, D. E.; Frank, I. E. Crossvalidation, bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat., 1988, 7, 18-22.
45. Hansch, C.; Kurup, A.; Garg, R.; Gao, H. Chem-bioinformatics and QSAR: A review of QSAR lacking positive hydrophobic terms. Chem. Rev., 2001, 101, 619-72
46. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graphics Model., 2002, 20, 269-76.
47. Dimmock, J. R.; Kumar, P.; Quail, J.W.; Pugazhenthi, U.; Yang, J.; Chen, M.; Reid, R. S.; Allen, T. M.; Kao, G. Y.; Cole S. P.; Batist, G.; Balzarini, J.; De Clercq, E. Synthesis and cytotoxic evaluation of some styryl ketones and related compound. Eur. J. Med. Chem., 1995, 30, 209-17.
48. De Vincenzo, R.; Ferlini, C.; Distefano, M.; Gaggini, C.; Riva, A.; Bombardelli, E.; Morazzoni, P.; Valenti, P.; Belluti, F.; Ranelletti, F. O.; Mancuso, S.; Scambia, G. In vitro evaluation of newly developed chalcone analogues in human cell lines. Cancer Chemothr. Pharmacol., 2000, 46, 305-12.
49. De Vincenzo, R.; Scambia, G.; Benedetti Panici P.; Ranelletti, F. O.; Bonanno, G.; Ercoli, A.; Delle Monache, F.; Ferrari, F.; Piantelli, M.; Mancuso, S. Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: Structure activity relationship. Anticancer Drug Des., 1995, 10, 481-90.
50. Dimmock, J. R.; Zello, G. A.; Oloo, E. O.; Quail, J. W.; Kraatz, H. B.; Perjési, P.; Aradi, F.; Takács-Novák, K.; Allen, T. M.; Santos, C. L.; Balzarini, J.; De Clercq, E.; Stables J. P. Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography. J. Med. Chem., 2002, 45, 3103-11.
51. Dimmock, J. R.; Jha, A.; Zello, G. A.; Quail, J. W.; Oloo, E. O.; Nienaber, K. H.; Kowalczyk, E. S.; Allen, T. M.; Santos, C. L.; De Clercq, E.; Balzarini, J.; Manavathu, E. K.; Stables, J. P. Cytotoxic N-[4-(3-aryl-3-oxo-1-propenyl) phenylcarbonyl]-3, 5- bis (phenylmethylene)-4-piperidones and related compounds. Eur. J. Med. Chem., 2002, 37, 961-72.
52. Kumar, S. K.; Hager, E.; Pettit, C.; Gurulingappa, H.; Davidson, N. E.; Khan, S. R. Design, synthesis, and evaluation of novel boronicchalcone derivatives as antitumor agents. J Med. Chem., 2003, 46, 2813-5.
53. Thistlethwaite, A. J.; Leeper, D. B.; Moylan III, M. D.; Nerlinger, B. S. pH distribution in human tumors. Int. J. Radiat. Oncol. Biol. Phys., 1985, 11, 1647-52.
54. Wike-Hooley, J. L.; Havenman, J.; Reinhold, J. S. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol., 1984, 2, 343-66.
55. Loewenthal, H.J.E. Protective Groups in Organic Chemistry, (McOmie JFW, ed) Plenum Press: London UK, 1973, pp.340-343.
56. Di Cesare, N.; Lakowicz, J. R. Chalcone-analogue fluorescent prfobes for saccharides signaling using the boronic acid group. Tetrahedron Let., 2002, 43, 2615-18.
57. Juven-Gerson, T.; Oren, M. Mdm2: The ups and downs. Mol. Med., 1999, 5, 71-83.
58. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification database. Nucleic Acids Res., 1998, 26, 3453-59.
59. Hansch, C.; Klein, T. Molecular graphics and QSAR in the study of enzyme-ligand interactions. Acc. Chem. Res., 1986, 19, 392-400.